# Palvella Therapeutics, Inc. (PVLA)

> Source: Nexqual · https://nexqual.com/PVLA · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Palvella Therapeutics, Inc. (PVLA), nexqual.com/PVLA" · informational, not investment advice.

**Price:** USD 127.34 (+3.88% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 122.58 · day 122.51–129.49 · 52w 68.96–161.38 · market cap $1.83B · NGM

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (15 analysts), mean target USD 228.93 (range 205–267).
- Total return with dividends: 1Y +74.1% vs S&P 500 +18.1%; 5Y -64.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-11, EPS estimate USD -1.74, revenue estimate $0K.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 15 analysts; mean target USD 228.93 (low 205, high 267).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | HC Wainwright & Co. | Target lowered | Buy | $270 → $246 |
| 2026-09-21 | Chardan Capital | Maintained | Buy | $240 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +74.1% | -64.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +74.4% | -18.8% |
| Volatility (annualized) | 80.9% | 97.8% |
| Max drawdown | -31.1% (Feb 2026→Jun 2026) | -98.1% (Oct 2021→Jul 2024) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/PVLA · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt